Health Care [ 2/12 ] | Biotechnology [ 19/74 ]
NASDAQ | Common Stock
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration.
It has strategic collaborations F.
Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA.
Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 12, 26 | -0.20 Increased by +45.95% | -0.26 Increased by +23.08% |
| Feb 26, 26 | -0.18 Increased by +63.27% | -0.43 Increased by +58.14% |
| Nov 6, 25 | -0.44 Decreased by -25.71% | -0.41 Decreased by -7.32% |
| Aug 7, 25 | -0.37 Decreased by -42.31% | -0.38 Increased by +2.63% |
| May 7, 25 | -0.37 Increased by +2.63% | -0.43 Increased by +13.95% |
| Feb 20, 25 | -0.49 Increased by +30.00% | -0.45 Decreased by -8.79% |
| Oct 31, 24 | -0.35 Increased by +35.19% | -0.33 Decreased by -6.06% |
| Aug 1, 24 | -0.26 Increased by +64.38% | -0.18 Decreased by -44.44% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 6.15 M Decreased by -15.00% | -25.13 M Increased by +4.53% | Decreased by -408.47% Decreased by -12.32% |
| Dec 31, 25 | 11.02 M Increased by +112.79% | -20.49 M Increased by +40.75% | Decreased by -185.97% Increased by +72.15% |
| Sep 30, 25 | 11.23 M Decreased by -26.90% | -32.17 M Decreased by -30.41% | Decreased by -286.43% Decreased by -78.39% |
| Jun 30, 25 | 6.46 M Decreased by -46.17% | -26.02 M Decreased by -46.87% | Decreased by -402.60% Decreased by -172.84% |
| Mar 31, 25 | 7.24 M Increased by +138.17% | -26.32 M Increased by +7.19% | Decreased by -363.66% Increased by +61.03% |
| Dec 31, 24 | 5.18 M Increased by +58.75% | -34.57 M Increased by +0.52% | Decreased by -667.82% Increased by +37.34% |
| Sep 30, 24 | 15.36 M Increased by +38.75% | -24.67 M Increased by +8.77% | Decreased by -160.57% Increased by +34.25% |
| Jun 30, 24 | 12.01 M Increased by +350.68% | -17.72 M Increased by +50.68% | Decreased by -147.56% Increased by +89.06% |